|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2004-11-3
|
|
pubmed:abstractText |
B-cell chronic lymphocytic leukaemia (B-CLL) can be divided into two clinical entities based on the immunoglobulin variable heavy chain (VH) gene mutation status, as cases with unmutated VH genes display a more aggressive disease with shorter survival time than mutated cases. The aim of this study was to investigate whether differences in cellular drug resistance could give an explanation for these divergent clinical courses.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cladribine,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Idarubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Heavy Chains,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin Variable Region,
http://linkedlifedata.com/resource/pubmed/chemical/Melphalan,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/fludarabine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0902-4441
|
|
pubmed:author |
pubmed-author:AleskogAnnaA,
pubmed-author:HöglundMartinM,
pubmed-author:LarssonRolfR,
pubmed-author:LaurellAnnaA,
pubmed-author:LindhagenElinE,
pubmed-author:NilssonKennethK,
pubmed-author:NygrenPeterP,
pubmed-author:RoosGöranG,
pubmed-author:RosenquistRichardR,
pubmed-author:SundströmChristerC,
pubmed-author:ThunbergUlfU,
pubmed-author:TobinGerardG
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
407-11
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15522062-Antineoplastic Agents,
pubmed-meshheading:15522062-Cell Differentiation,
pubmed-meshheading:15522062-Cell Line, Tumor,
pubmed-meshheading:15522062-Cladribine,
pubmed-meshheading:15522062-Cyclophosphamide,
pubmed-meshheading:15522062-Cytarabine,
pubmed-meshheading:15522062-DNA Mutational Analysis,
pubmed-meshheading:15522062-Doxorubicin,
pubmed-meshheading:15522062-Drug Resistance, Neoplasm,
pubmed-meshheading:15522062-Gene Rearrangement, B-Lymphocyte, Heavy Chain,
pubmed-meshheading:15522062-Genes, Immunoglobulin,
pubmed-meshheading:15522062-Humans,
pubmed-meshheading:15522062-Idarubicin,
pubmed-meshheading:15522062-Immunoglobulin Heavy Chains,
pubmed-meshheading:15522062-Immunoglobulin Variable Region,
pubmed-meshheading:15522062-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:15522062-Life Tables,
pubmed-meshheading:15522062-Melphalan,
pubmed-meshheading:15522062-Prednisolone,
pubmed-meshheading:15522062-Survival Analysis,
pubmed-meshheading:15522062-Vidarabine,
pubmed-meshheading:15522062-Vincristine
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
|
|
pubmed:affiliation |
Department of Internal Medicine, Uppsala University, Uppsala, Sweden. anna.aleskog@medsci.uu.se
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
